Literature DB >> 17198909

The G-231A polymorphism in the endothelin-A receptor gene is associated with lower aortic pressure in patients with dilated cardiomyopathy.

Ralph Telgmann1, Bassam A Harb, Cemil Ozcelik, Andreas Perrot, Jacqueline Schönfelder, Andreas Nonnenmacher, Marcus Brand, Klaus Schmidt-Petersen, Rainer Dietz, Reinhold Kreutz, Karl-Josef Osterziel, Martin Paul, Stefan-Martin Brand-Herrmann.   

Abstract

BACKGROUND: The endothelin system (ES) plays an important role in blood pressure (BP) regulation and also in the pathophysiology of idiopathic dilated cardiomyopathy (DCM). Recently, we demonstrated that a genetic polymorphism in the endothelin A (ET(A)) receptor gene was associated with survival in DCM patients. The aim of this study was to determine whether polymorphisms in the ET(A) receptor gene might be associated with the severity of DCM.
METHODS: One hundred twenty-four consecutively recruited unrelated patients with DCM, who underwent a detailed phenotyping protocol, were genotyped for the ET(A) receptor G-231A polymorphism using a hybridization technique with allele-specific oligonucleotides.
RESULTS: The exon 1 G-231A polymorphism of the ET(A) receptor gene, upstream of the translation start site, was significantly associated with directly measured intra-aortic pressure in that -231A allele carriers had significantly lower systolic (P = .0043), as well as mean (P = .0016) and diastolic (P = .0041) aortic pressure compared to noncarriers. The association of ET(A) G-231A with aortic pressure was independent from other factors such as prior medication, left ventricular end-diastolic diameter, age, gender, and New York Heart Association (NYHA) functional classification. However, no such association was seen for cuff BP and survival rates were not significantly different between -231A allele carriers and -231G homozygotes (log rank test, P = .66). No significant association with any other parameter investigated in the present study could be observed, even when men and women were analyzed separately.
CONCLUSIONS: Our results suggest an association of genetic variation in the ET(A) receptor gene with aortic pressure in patients with DCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198909     DOI: 10.1016/j.amjhyper.2006.06.016

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade.

Authors:  Catherine K Hathaway; Ruriko Grant; John R Hagaman; Sylvia Hiller; Feng Li; Longquan Xu; Albert S Chang; Victoria J Madden; C Robert Bagnell; Mauricio Rojas; Hyung-Suk Kim; Bingruo Wu; Bin Zhou; Oliver Smithies; Masao Kakoki
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study.

Authors:  Donna K Arnett; Richard B Devereux; Dabeeru C Rao; Na Li; Weihong Tang; Rachel Kraemer; Steven A Claas; Joanlise M Leon; Ulrich Broeckel
Journal:  J Hypertens       Date:  2009-08       Impact factor: 4.844

3.  Polymorphisms in nitric oxide synthase and endothelin genes among children with obstructive sleep apnea.

Authors:  Siriporn Chatsuriyawong; David Gozal; Leila Kheirandish-Gozal; Rakesh Bhattacharjee; Ahamed A Khalyfa; Yang Wang; Wasana Sukhumsirichart; Abdelnaby Khalyfa
Journal:  BMC Med Genomics       Date:  2013-09-06       Impact factor: 3.063

Review 4.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

5.  Genetic variance in nitric oxide synthase and endothelin genes among children with and without endothelial dysfunction.

Authors:  Siriporn Chatsuriyawong; David Gozal; Leila Kheirandish-Gozal; Rakesh Bhattacharjee; Ahamed A Khalyfa; Yang Wang; Hakon Hakonarson; Brendan Keating; Wasana Sukhumsirichart; Abdelnaby Khalyfa
Journal:  J Transl Med       Date:  2013-09-25       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.